These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15000896)

  • 1. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.
    Li KY; Li X; Cheng ZN; Peng WX; Zhang BK; Li HD
    Acta Pharmacol Sin; 2004 Mar; 25(3):390-4. PubMed ID: 15000896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia.
    Li KY; Li X; Cheng ZN; Zhang BK; Peng WX; Li HD
    Eur J Clin Pharmacol; 2005 Jan; 60(11):791-5. PubMed ID: 15599502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia.
    Li Q; Su YA; Liu Y; Chen JX; Tan YL; Yang FD; Si TM
    Clin Pharmacokinet; 2014 May; 53(5):455-65. PubMed ID: 24385309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders.
    Winter HR; Earley WR; Hamer-Maansson JE; Davis PC; Smith MA
    J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):81-98. PubMed ID: 18294091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.
    Zhou ZL; Li X; Peng HY; Yu XY; Yang M; Su FL; Wang F; Zhu RH; Deng CY; Lin QX; Wang CY; Li WB; Lin SG; Li HD
    Acta Pharmacol Sin; 2006 Mar; 27(3):381-6. PubMed ID: 16490177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
    Potkin SG; Thyrum PT; Alva G; Bera R; Yeh C; Arvanitis LA
    J Clin Psychopharmacol; 2002 Apr; 22(2):121-30. PubMed ID: 11910256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
    Potkin SG; Thyrum PT; Alva G; Carreon D; Yeh C; Kalali A; Arvanitis LA;
    J Clin Psychopharmacol; 2002 Apr; 22(2):174-82. PubMed ID: 11910263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders.
    Strakowski SM; Keck PE; Wong YW; Thyrum PT; Yeh C
    J Clin Psychopharmacol; 2002 Apr; 22(2):201-5. PubMed ID: 11910267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
    Winter HR; DeVane CL; Figueroa C; Ennis DJ; Hamer-Maansson JE; Davis PC; Smith MA
    Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications.
    Bui K; Earley W; Nyberg S
    Curr Med Res Opin; 2013 Jul; 29(7):813-25. PubMed ID: 23574265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders.
    McConville BJ; Arvanitis LA; Thyrum PT; Yeh C; Wilkinson LA; Chaney RO; Foster KD; Sorter MT; Friedman LM; Brown KL; Heubi JE
    J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of a possible interaction between quetiapine and armodafinil in patients with schizophrenia: an open-label, multiple-dose study.
    Darwish M; Bond M; Hellriegel ET; Youakim JM; Yang R; Robertson P
    J Clin Pharmacol; 2012 Sep; 52(9):1399-409. PubMed ID: 21903893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic mechanism of quetiapine in vivo with clinical therapeutic dose.
    Li KY; Li X; Cheng ZN; Li HD
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):83-6. PubMed ID: 15834460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment.
    Thyrum PT; Wong YW; Yeh C
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 May; 24(4):521-33. PubMed ID: 10958148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review.
    Sparshatt A; Taylor D; Patel MX; Kapur S
    J Clin Psychiatry; 2011 Aug; 72(8):1108-23. PubMed ID: 21294996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry.
    Li KY; Cheng ZN; Li X; Bai XL; Zhang BK; Wang F; Li HD
    Acta Pharmacol Sin; 2004 Jan; 25(1):110-4. PubMed ID: 14704131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
    Wong YW; Yeh C; Thyrum PT
    J Clin Psychopharmacol; 2001 Feb; 21(1):89-93. PubMed ID: 11199955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
    Nord M; Nyberg S; Brogren J; Jucaite A; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1357-66. PubMed ID: 21477416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.